Ronan Kelly
Medical Oncology · Dallas, TXNPI 1477846715
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 44.0% of the total. 2025 is the largest year on record at $403,033, more than ten times the $18,713 reported in 2019. Among medical oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 573 payments — averaging $1904.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$480K
- Astellas Pharma US Inc$132K
- Daiichi Sankyo Inc.$120K
- Beone Medicines USA, Inc.$103K
- Merck$63K
- AstraZeneca$59K
- plus $133K from 18 others
Across 74 payments — averaging $16,713 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$587K
- E.r. Squibb & Sons, L.L.C.$164K
- Exact Sciences$114K
- AstraZeneca$95K
- Macrogenics, Inc.$92K
- Merck$43K
- plus $141K from 4 others
What the payments were for
- Consulting fees$473,71343%
- Speaking & faculty fees$481,70744%
- Travel & lodging$126,47212%
- Food & beverage$9,1601%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 206 | $480,320 |
| Astellas Pharma US Inc | 81 | $132,460 |
| Daiichi Sankyo Inc. | 63 | $119,895 |
| Beone Medicines USA, Inc. | 62 | $102,957 |
| Merck | 31 | $63,200 |
| AstraZeneca | 31 | $58,993 |
| Exact Sciences | 19 | $22,227 |
| Novartis | 10 | $17,746 |
| Astrazeneca UK Limited | 5 | $14,566 |
| EMD Serono, Inc. | 4 | $13,000 |
| Gilead | 4 | $11,170 |
| Beigene USA, Inc. | 8 | $9,090 |
| Lilly USA, LLC | 9 | $7,554 |
| Amgen | 5 | $6,860 |
| Novocure Inc. | 2 | $6,742 |
| Ipsen Biopharmaceuticals, Inc | 1 | $6,200 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $5,610 |
| Eisai Inc. | 2 | $4,080 |
| Astellas Pharma Global Development | 13 | $3,419 |
| Jazz Pharmaceuticals Inc. | 1 | $3,098 |
| US Endoscopy | 4 | $1,725 |
| AbbVie | 4 | $65 |
| Siemens Medical Solutions USA, Inc. | 4 | $60 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,091,052 in reported general payments places this provider in the 95th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Dallas
- Moshe LevyDallas$5.1M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Joyce O'ShaughnessyDallas$1.3M
- Thomas HutsonDallas$944K
- Heather McArthurDallas$314K
- Tian ZhangDallas$286K
- Micah BurchDallas$221K
- David JohnsonDallas$212K
- Kartik KonduriDallas$191K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.